rs267607027
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_015474.4(SAMHD1):c.490C>T(p.Arg164*) variant causes a stop gained change. The variant allele was found at a frequency of 0.00000558 in 1,613,890 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.0000066 ( 0 hom., cov: 31)
Exomes 𝑓: 0.0000055 ( 0 hom. )
Consequence
SAMHD1
NM_015474.4 stop_gained
NM_015474.4 stop_gained
Scores
3
3
1
Clinical Significance
Conservation
PhyloP100: 5.63
Genes affected
SAMHD1 (HGNC:15925): (SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1) This gene may play a role in regulation of the innate immune response. The encoded protein is upregulated in response to viral infection and may be involved in mediation of tumor necrosis factor-alpha proinflammatory responses. Mutations in this gene have been associated with Aicardi-Goutieres syndrome. [provided by RefSeq, Mar 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 20-36935048-G-A is Pathogenic according to our data. Variant chr20-36935048-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 4069.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr20-36935048-G-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SAMHD1 | NM_015474.4 | c.490C>T | p.Arg164* | stop_gained | 4/16 | ENST00000646673.2 | NP_056289.2 | |
SAMHD1 | NM_001363729.2 | c.490C>T | p.Arg164* | stop_gained | 4/15 | NP_001350658.1 | ||
SAMHD1 | NM_001363733.2 | c.490C>T | p.Arg164* | stop_gained | 4/16 | NP_001350662.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SAMHD1 | ENST00000646673.2 | c.490C>T | p.Arg164* | stop_gained | 4/16 | NM_015474.4 | ENSP00000493536.2 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 152066Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
1
AN:
152066
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251460Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135894
GnomAD3 exomes
AF:
AC:
1
AN:
251460
Hom.:
AF XY:
AC XY:
1
AN XY:
135894
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000547 AC: 8AN: 1461824Hom.: 0 Cov.: 30 AF XY: 0.00000550 AC XY: 4AN XY: 727216
GnomAD4 exome
AF:
AC:
8
AN:
1461824
Hom.:
Cov.:
30
AF XY:
AC XY:
4
AN XY:
727216
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000658 AC: 1AN: 152066Hom.: 0 Cov.: 31 AF XY: 0.0000135 AC XY: 1AN XY: 74256
GnomAD4 genome
AF:
AC:
1
AN:
152066
Hom.:
Cov.:
31
AF XY:
AC XY:
1
AN XY:
74256
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
1
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Aicardi-Goutieres syndrome 5 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 11, 2023 | This sequence change creates a premature translational stop signal (p.Arg164*) in the SAMHD1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SAMHD1 are known to be pathogenic (PMID: 19525956, 22461318). This variant is present in population databases (rs267607027, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with Aicardi-Goutieres syndrome (PMID: 20842748, 22174685). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 4069). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 2010 | - - |
Likely pathogenic, criteria provided, single submitter | research | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Dec 03, 2018 | The homozygous p.Arg164Ter variant in SAMHD1 was identified by our study in two unrelated individuals with Aicardi-Goutieres syndrome. This variant was absent from large population studies and has been reported pathogenic by OMIM in ClinVar (Variation ID: 4069). The p.Arg164Ter variant in SAMHD1 has been reported in 6 individuals (including 4 Turkish siblings with the variant in the homozygous state and 2 siblings with a Maltese father and the variant in the compound heterozygous state) with Aicardi-Goutieres syndrome and segregated with disease in all 6 affected relatives from 2 families (PMID: 22174685, 20842748). The presence of this variant in combination with a variant reported pathogenic by OMIM in ClinVar (Variation ID: 4067) and in two siblings with Aicardi-Goutieres syndrome increases the likelihood that the p.Arg164Ter variant is pathogenic (PMID: 20358604). This nonsense variant leads to a premature termination codon at position 164, which is predicted to lead to a truncated or absent protein. At least two loss of function variants across multiple exons have been reported in association with Aicardi-Goutieres in ClinVar. Loss of function of the SAMHD1 gene is a moderately established disease mechanism in autosomal recessive Aicardi-Goutieres syndrome. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PM2, PVS1_Moderate, PP1, PM3_Supporting (Richards 2015). - |
Aicardi Goutieres syndrome Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Oct 19, 2020 | - - |
Aicardi-Goutieres syndrome 5;C3280721:Chilblain lupus 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 29, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
Vest4
0.98
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DL_spliceai
Position offset: -19
Find out detailed SpliceAI scores and Pangolin per-transcript scores at